Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Nutrien Ltd (NTR) Price & Performance

BioNTech SE - ADRTrade
Nutrien LtdTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Nutrien Ltd — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Nutrien Ltd trades at $66.6 (market cap $32.05B). The key difference: Nutrien Ltd is the larger of the two by market cap, and Nutrien Ltd pays a 3.27% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BNTXNTR
Market Cap
$23.31B$32.05B
Sector
HealthBasic Materials
52-Week High
$119.34$83.94
52-Week Low
$83.89$53.64
Enterprise Value
$6.60B$43.86B
Dividend Yield
3.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.

The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.

Nutrien Ltd

Nutrien (NTR) trades at $66.85, up 0.81% today, with a bearish technical signal despite neutral oscillators. Recent Q2 2026 earnings missed EPS estimates but beat on revenue, driven by higher potash prices. The company maintains a stable dividend of $0.55 per share and shows improving net income margins, though cash flow trends have weakened. Analyst consensus is bullish with a $76.17 price target, highlighting structural advantages in nitrogen assets.

The outlook is mixed: strong fundamentals and analyst support suggest upside, but technical weakness and volatile earnings pose risks. Key opportunities include exposure to agricultural cycles and cost advantages; risks involve input cost pressures and execution challenges in a competitive fertilizer market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Nutrien Ltd

Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.

Read more on NTR